Clinical Applications for the Central Nervous System

2007 ◽  
pp. 45-74
Author(s):  
Dominique Delbeke
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Clinical Applications ◽  
The Central Nervous System

scholarly journals Convection-enhanced delivery to the central nervous system

2015 ◽  
Vol 122 (3) ◽  
pp. 697-706 ◽  
Author(s):  
Russell R. Lonser ◽  
Malisa Sarntinoranont ◽  
Paul F. Morrison ◽  
Edward H. Oldfield
Keyword(s):  
Drug Delivery ◽  
Central Nervous System ◽  
Clinical Trials ◽  
Nervous System ◽  
Convective Flow ◽  
Clinical Applications ◽  
Systemic Delivery ◽  
Convection Enhanced Delivery ◽  
The Central Nervous System ◽  
Real Time Tracking

Convection-enhanced delivery (CED) is a bulk flow–driven process. Its properties permit direct, homogeneous, targeted perfusion of CNS regions with putative therapeutics while bypassing the blood-brain barrier. Development of surrogate imaging tracers that are co-infused during drug delivery now permit accurate, noninvasive real-time tracking of convective infusate flow in nervous system tissues. The potential advantages of CED in the CNS over other currently available drug delivery techniques, including systemic delivery, intrathecal and/or intraventricular distribution, and polymer implantation, have led to its application in research studies and clinical trials. The authors review the biophysical principles of convective flow and the technology, properties, and clinical applications of convective delivery in the CNS.

scholarly journals Pioneers in the cisterna magna puncture

2020 ◽  
Vol 78 (3) ◽  
pp. 176-178
Author(s):  
Thiago Ferreira Simões DE SOUZA
Keyword(s):  
Central Nervous System ◽  
Cerebrospinal Fluid ◽  
Nervous System ◽  
Clinical Applications ◽  
Alternative Route ◽  
Cisterna Magna ◽  
Relative Safety ◽  
The Central Nervous System ◽  
Promising Source ◽  
Diagnosis Of Diseases

Abstract At the beginning of the 20th century, cerebrospinal fluid (CSF) collection and analysis emerged as a promising aid in the diagnosis of diseases of the central nervous system. It was obtained through the established procedure of lumbar puncture, described by Heinrich Quinke in 1891. The search for an alternative way to gather the CSF emerged in animal research, highlighting the cisterna magna as a promising source, with relative safety when performed by someone trained. Described initially and in detail by James Ayer in 1920, the procedure was widely adopted by neurologists and psychiatrists at the time, featuring its multiple advantages and clinical applications. After a period of great procedure use and exponential data collection, its complications and risks relegated the puncture of the cisterna magna as an alternative route that causes fear and fascination in modern Neurology.

Clinical Applications

2016 ◽  
pp. 236-252
Author(s):  
Elson L. So
Keyword(s):  
Intensive Care Unit ◽  
Central Nervous System ◽  
Nervous System ◽  
Specific Treatment ◽  
Clinical Problem ◽  
Clinical Applications ◽  
Neural Function ◽  
Central Nervous System Disorders ◽  
Progression Of Disease ◽  
The Central Nervous System

Many electrophysiological assessment and techniques of clinical neurophysiology can be used in the assessment of patients with suspected disease of the central nervous system. Each of the techniques is applied either to assist clinicians in assessing disease of the central nervous system or, less commonly, to monitor changes in neural function. These techniques can be used to monitor neural function in observing progression of disease, such as the frequency of seizures, or improvement in a patient’s condition with specific treatment. They are also used in the intensive care unit and operating room to identify progressive neural damage. The clinical neurophysiological testing technique that is most appropriate for a patient depends on the clinical problem, and, often, some combination of techniques best provides the necessary data. This chapter focuses on the application of clinical neurophysiological techniques in assessing patients with suspected central nervous system disorders.

scholarly journals Non-Viral Delivery of RNA Gene Therapy to the Central Nervous System

Pharmaceutics ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 165
Author(s):  
Ellen S. Hauck ◽  
James G. Hecker
Keyword(s):  
Gene Therapy ◽  
Central Nervous System ◽  
Nervous System ◽  
Nucleic Acid ◽  
Gene Delivery ◽  
Dna Delivery ◽  
Clinical Applications ◽  
Cationic Lipids ◽  
Viral Dna ◽  
The Central Nervous System

Appropriate gene delivery systems are essential for successful gene therapy in clinical medicine. Lipid-mediated nucleic acid delivery is an alternative to viral vector-mediated gene delivery and has the following advantages. Lipid-mediated delivery of DNA or mRNA is usually more rapid than viral-mediated delivery, offers a larger payload, and has a nearly zero risk of incorporation. Lipid-mediated delivery of DNA or RNA is therefore preferable to viral DNA delivery in those clinical applications that do not require long-term expression for chronic conditions. Delivery of RNA may be preferable to non-viral DNA delivery in some clinical applications, since transit across the nuclear membrane is not necessary, and onset of expression with RNA is therefore even faster than with DNA, although both are faster than most viral vectors. Delivery of RNA to target organ(s) has previously been challenging due to RNA’s rapid degradation in biological systems, but cationic lipids complexed with RNA, as well as lipid nanoparticles (LNPs), have allowed for delivery and expression of the complexed RNA both in vitro and in vivo. This review will focus on the non-viral lipid-mediated delivery of RNAs, including mRNA, siRNA, shRNA, and microRNA, to the central nervous system (CNS), an organ with at least two unique challenges. The CNS contains a large number of slowly dividing or non-dividing cell types and is protected by the blood brain barrier (BBB). In non-dividing cells, RNA-lipid complexes demonstrated increased transfection efficiency relative to DNA transfection. The efficiency, timing of the onset, and duration of expression after transfection may determine which nucleic acid is best for which proposed therapy. Expression can be seen as soon as 1 h after RNA delivery, but duration of expression has been limited to 5–7 h. In contrast, transfection with a DNA lipoplex demonstrates protein expression within 5 h and lasts as long as several weeks after transfection.

Fast Analytical Sensing Technology: Microelectrode-Based Recordings of Tonic and Phasic Neurotransmitter Signalling in the Mammalian Brain

2018 ◽  
pp. 500-510
Author(s):  
Michelle L. Humeiden ◽  
Jorge E. Quintero ◽  
John T. Slevin ◽  
Greg A. Gerhardt
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Clinical Applications ◽  
Mammalian Brain ◽  
Excitatory Neurotransmitter ◽  
Ideal Candidate ◽  
Ca1 Region ◽  
Sensing Technology ◽  
The Central Nervous System ◽  
The Brain

Communication in the nervous system is predominately chemical. However, understanding of neurotransmitter signalling in normal and diseased states remains lacking. Electrochemically based biosensors can detect chemical messengers on a near-real timescale, allowing exploration of neurotransmitter systems to bring into focus the functioning elements of this critical means of communication. Glutamate, the predominant excitatory neurotransmitter of the central nervous system, is an ideal candidate for measurement with biosensors. With biosensors, it has been found that spontaneous glutamate signals in the dentate gyrus are enhanced in kindled animals. Meanwhile, in a model of epilepsy, the utility of detecting and the dynamism of glutamate signalling become apparent as tonic glutamate levels and rapid, spontaneous phasic glutamate signals show a correlation with seizure activity in the CA1 region of rodents. The ability of these biosensors to detect neurotransmitters in the brain is promising for clinical applications to monitor and, eventually, treat epilepsy.

Diffusion MR imaging of the central nervous system: clinical applications [in French]

2006 ◽  
Vol 30 (1) ◽  
pp. 71
Author(s):  
M. Hamon ◽  
O. Coskun ◽  
P. Courthéoux ◽  
J. Théron ◽  
L. Leclerc
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Mr Imaging ◽  
Clinical Applications ◽  
Diffusion Mr ◽  
The Central Nervous System ◽  
Diffusion Mr Imaging

scholarly journals Oxytocin and Pregnancy

2021 ◽  
Author(s):  
Haiwen Yu ◽  
Yuting Cheng ◽  
Yiwen Lu ◽  
Wei Wu ◽  
Qiuqin Tang
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Gestational Hypertension ◽  
Smooth Muscles ◽  
Clinical Applications ◽  
Peripheral Tissues ◽  
Oxytocin Receptors ◽  
The Central Nervous System ◽  
Oxytocin Level ◽  
In Pregnancy

Oxytocin, an important neuropeptide, exerts a wide influence on the central nervous system and the peripheral tissues. In the central nervous system, the oxytocin gene expression is mainly shown to be present in neurons in the hypothalamic paraventricular and supraoptic nuclei. Oxytocin gene also transcribes in the peripheral tissues such as uterus, placenta, and amnion. Oxytocin receptors can be founded in many tissues in humans, like the uterine, ovary, testis, kidney, and so on. And just in the same tissue, due to the variation of physiology factors, the amount of oxytocin changes a lot. Oxytocin secretion is closely linked with pregnancy advancing. During labor, the contractions of uterine smooth muscles and oxytocin secretion are inseparable. Moreover, oxytocin is also responsible for stimulating milk ejection after parturition. Oxytocin is associated with many diseases. Poor regulation of oxytocin may cause postpartum depression and infantile autism. In terms of physiology, fatal heart failure and gestational hypertension are concerned with oxytocin level. In this chapter, we will discuss the oxytocin in pregnancy as well as its clinical applications.

Sign in / Sign up

Export Citation Format

Share Document